Notwithstanding that sentiment, though, there are definitely some shortcomings in this bill—some shortcomings that, as Mr Muller pointed out, no doubt will be usurped by the proposed therapeutic products bill in due course. So, on this occasion, it's not so important. We view it, on this side of the House, as a perfectly adequate stopgap measure.